Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  The Lancet Oncology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(12)70560-0PMID 23306100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.

  2012cited by this paper
• Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

  2012cited by this paper
• Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

  2012cited by this paper
• A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

  2012cited by this paper
• Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

  2011cited by this paper
• The economic burden of prostate cancer

  2011cited by this paper
• Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.

  2010cited by this paper
• Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

  2009cited by this paper
• The estimation of average hazard ratios by weighted Cox regression

  2009cited by this paper
• Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.

  2008cited by this paper
• Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

  2008cited by this paper
• Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.

  2008cited by this paper
• Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

  2007cited by this paper
• Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

  2006cited by this paper
• Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.

  2006cited by this paper
• Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.

  2005cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.

  2003cited by this paper
• Outcome predictions for patients with metastatic prostate cancer.

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Adjuvant mitozantrone chemotherapy in advanced prostate cancer

  2000cited by this paper
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

  1999cited by this paper
• Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

  1998cited by this paper
• Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

  1997cited by this paper
• RE: EDITORIAL COMMENT: TAKING ON PROSTATE CANCER

  1997cited by this paper
• Proportional hazards tests and diagnostics based on weighted residuals

  1994cited by this paper

• The Optimal Management of Patients with Prostate Cancer with Oligometastatic Disease and Low Metastatic Burden in the PSMA-PET Era

  2026influential citation
• Exploring treatment models for oligometastatic castration-sensitive prostate cancer: evolution of therapeutic strategies.

  2026cites this paper
• [Multidisciplinary management of elderly patients with advanced prostate cancer].

  2026cites this paper
• Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration).

  2026cites this paper
• Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study.

  2026cites this paper
• Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy

  2025cites this paper
• Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UK

  2025cites this paper
• Investigating the Latest Evidence from Phase III Trials Supporting Treatment Options for De novo Clinically Lymph Node-Positive Hormone-Sensitive Prostate Cancer

  2025cites this paper
• Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences

  2025cites this paper
• Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update).

  2025cites this paper
• Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review

  2025cites this paper
• Personalized intensification of treatment for hormone-sensitive prostate cancer

  2025cites this paper
• Metastatic Hormone-Sensitive Prostate Cancer: The Role of Docetaxel in Triple-Therapy Regimens

  2025cites this paper
• Advances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer

  2025cites this paper
• Recent advances in drug treatment for prostate cancer

  2025cites this paper
• Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey

  2025cites this paper
• Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation

  2025cites this paper
• The contemporary management of prostate cancer

  2025cites this paper
• Real‑world data on the outcomes of upfront docetaxel in hormone‑sensitive metastatic prostate cancer.

  2025cites this paper
• Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification.

  2025cites this paper
• Bayesian analysis of restricted mean survival time adjusted for covariates using pseudo-observations

  2025cites this paper
• A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer

  2025cites this paper
• Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.

  2025cites this paper
• Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study

  2025cites this paper
• The Predictive Role of the Gleason Score in Determining Prognosis to Systematic Treatment in Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-Analysis

  2025cites this paper
• Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data.

  2025cites this paper
• Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis.

  2025cites this paper
• A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer

  2025cites this paper
• Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis

  2025cites this paper
• Is [177Lu]Lu-PSMA-617 Redefining Value in mCRPC Care? A Meta-Analysis of Clinical and Economic Endpoints

  2025cites this paper
• Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

  2025cites this paper
• Packing the Punch: Current and Emerging Treatment Strategies in Metastatic Castration-Sensitive Prostate Cancer

  2025cites this paper
• Current landscape in first-line treatment of metastatic hormone sensitive prostate cancer: a cost-effectiveness focused review

  2025cites this paper
• Real-World Outcomes of Upfront Abiraterone in Metastatic Castration-Sensitive Prostate Cancer Patients at a Tertiary Care Hospital

  2025cites this paper
• Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience.

  2025cites this paper
• Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer

  2025influential citation
• Impact of Inequalities in Treatment for Prostate Cancer Affecting Demand for Secondary and Tertiary Services: Secondary Analysis of Linked National Datasets.

  2025cites this paper
• Docetaxel Rechallenge After Chemohormonal Therapy in High-Volume Metastatic Castration-Sensitive Prostate Cancer

  2025cites this paper
• Características y desenlaces de supervivencia de pacientes con cáncer de próstata metastásico hormonosensible en un centro oncológico en Medellín, Colombia

  2025cites this paper
• Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer

  2025cites this paper
• Addition of androgen-receptor pathway inhibitors to standard of care in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

  2025cites this paper
• Systemic treatment of metastatic castration-sensitive prostate cancer: A meta-analysis of efficacy and safety

  2025cites this paper
• Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients

  2025cites this paper
• Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale.

  2024cites this paper
• [UPFRONT DOCETAXEL WITH ANDROGEN DEPRIVATION THERAPY IN MALES WITH HIGH-VOLUME METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: RESULTS OF A SINGLE-INSTITUTION SERIES].

  2024cites this paper
• Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

  2024cites this paper
• Darolutamide in Japanese patients with metastatic hormone‐sensitive prostate cancer: Phase 3 ARASENS subgroup analysis

  2024cites this paper
• Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review

  2024cites this paper
• Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives

  2024cites this paper
• A nanoprodrug derived from branched poly (ethylene glycol) recognizes prostate-specific membrane antigen to precisely suppress prostate cancer progression.

  2024cites this paper
• Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

  2024cites this paper
• How We Treat Metastatic Castration-Sensitive Prostate Cancer

  2024cites this paper
• Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis

  2024influential citation
• Clinical efficacy of current treatments for high-volume metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis

  2024cites this paper
• Long non-coding RNAs: regulators of autophagy and potential biomarkers in therapy resistance and urological cancers

  2024cites this paper
• Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium

  2024cites this paper
• Cardio-oncology in advanced prostate cancer

  2024cites this paper
• Patient Preferences for Metastatic Prostate Cancer Treatment: A Discrete Choice Experiment.

  2024cites this paper
• Comment on Real-world Efficacy and Toxicity Analysis of Abiraterone Acetate versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer in Asian Patients.

  2024cites this paper
• Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.

  2024cites this paper
• Management of advanced prostate cancer in the Asia‐Pacific region: Summary of the Asia‐Pacific Advanced Prostate Cancer Consensus Conference 2023

  2024cites this paper
• Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection.

  2024cites this paper
• Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer

  2024cites this paper
• Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.

  2024cites this paper
• Research protocol for an observational health data analysis to assess the applicability of randomized controlled trials focusing on newly diagnosed metastatic prostate cancer using real-world data: PIONEER IMI’s “big data for better outcomes” program

  2024cites this paper
• New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact

  2024cites this paper
• Intensification of androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: patient selection and overview of doublet and triplet therapy data.

  2024cites this paper
• Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy

  2024cites this paper
• Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer

  2024cites this paper
• Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

  2024cites this paper
• Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence

  2024cites this paper
• Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis

  2024cites this paper
• Recomendaciones de tratamiento en el cáncer de próstata hormonosensible metastásico: selección de pacientes

  2024cites this paper
• Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer

  2024cites this paper
• Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

  2024cites this paper
• From biology to the clinic — exploring liver metastasis in prostate cancer

  2024cites this paper
• EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

  2024cites this paper
• Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia.

  2024cites this paper
• Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer

  2024cites this paper
• Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives.

  2024cites this paper
• The Current Therapeutic Landscape for Metastatic Prostate Cancer

  2024cites this paper
• Research progress of MUC1 in genitourinary cancers

  2024cites this paper
• Mise au point et stratégies thérapeutiques dans le cancer de la prostate avancé et métastatique

  2023cites this paper
• Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort

  2023cites this paper
• Breaking Through Resistance in mCRPC: Enzalutamide analogues as Effective Anticancer Agents for Enhanced Male Survival

  2023cites this paper
• Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy

  2023cites this paper
• De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?

  2023cites this paper
• TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis.

  2023cites this paper
• Advances in non-radioactive PSMA-targeted small molecule-drug conjugates in the treatment of prostate cancer.

  2023cites this paper
• Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer

  2023cites this paper
• Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.

  2023cites this paper
• Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer

  2023cites this paper
• Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

  2023cites this paper
• New drug approvals in prostate cancer and their effect on the treatment landscape.

  2023cites this paper
• Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials

  2023influential citation
• Clinical Variables in the Diagnosis and Treatment of Advanced Hormone Sensitive Prostate Cancer

  2023cites this paper
• Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program

  2023cites this paper
• Current Management and Future Treatment Strategies for Patients with Metastatic Hormone-Sensitive Prostate Cancer

  2023cites this paper
• Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta‐analysis

  2023cites this paper